Introduction
============

Active surveillance (AS) is a treatment option, with curative intent, that is widely accepted in many cancer treatment guidelines for patients with very low risk prostate cancer (PC) \[[@b1-crt-2016-477],[@b2-crt-2016-477]\]. Currently, there are insufficient long-term data regarding the outcomes of patients with PC to reliably identify individuals who would be suitable for AS, as well as to define standardized criteria for definitive treatment of patients who are on AS. Indeed, only one study is currently available, which consisted of a 15-year follow-up of AS in patients with PC \[[@b3-crt-2016-477]\]. In their study, Klotz et al. \[[@b3-crt-2016-477]\] reported an overall survival (OS) rate of 62% and a disease-specific survival (DSS) of 94.3%, with 27% of patients undergoing definitive treatment over the 15-year period. At the end of the 15-year observation period, 55.0% of patients remained untreated and on surveillance. Therefore, a significant proportion of patients initially placed on AS required definitive treatment, and some of these did not receive treatment at the appropriate time. Therefore, the major challenge of AS is to differentiate patients with significant PC disease status from those with an insignificant disease status.

The heterogeneous nature of PC is the principal factor underlying our current inability to specifically identify those patients in whom the disease is likely to progress \[[@b4-crt-2016-477]\]. Identification of standardized criteria for definitive treatment is further complicated by ethnicity-specific differences in the disease course of PC. As an example, in Asian populations, including Koreans, patients with PC tend to have a higher Gleason score and advanced stage than their Western counterparts \[[@b5-crt-2016-477]-[@b7-crt-2016-477]\]. Thus, the current AS selection criteria, which are based on Western studies, should cautiously be applied to Asian populations \[[@b8-crt-2016-477],[@b9-crt-2016-477]\], which limits the widespread use of AS in Asia. Therefore, the development of more stringent AS protocols for Asian patients based on well-designed, large clinical studies, is urgently needed \[[@b10-crt-2016-477]\]. Accordingly, this multicenter retrospective study was conducted to identify potentially appropriate selection criteria for AS in Korean patients with PC. A secondary goal was to compare the validity of our new criteria to various Western criteria for our study population.

Materials and Methods
=====================

1. Ethic statement
------------------

This study was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (H-1507-005-683) and each participating institution.

2. Study design and patient eligibility
---------------------------------------

We conducted a multicenter, retrospective study among Korean patients with PC who would now be potential candidates for AS, but actually underwent radical prostatectomy between 2000 and 2012. Eight institutions were included in the study, Seoul National University Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Asan Medical Center, Pusan National University Hospital, Chonnam National University Hwasun Hospital, Kyungpook National University Hospital, and Inje University Haeundae Paik Hospital. As these were low-risk patients, only pelvic lymph node dissection was performed for selected cases (about 20%). We evaluated pathological outcomes and biochemical recurrence (BCR)--free survival. Inclusion criteria for patient selection were as follows: histologically proven adenocarcinoma of the prostate, diagnosed using contemporary transrectal ultrasound-guided prostate biopsy (≥ 10 cores), with a clinical staging of T1c-T2a; prebiopsy prostate-specific antigen (PSA) ≤ 10 ng/mL; and a biopsy Gleason score ≤ 6. The exclusion criteria were as follows: prior radiation therapy; androgen deprivation therapy or any other treatment for PC, such as high-intensity focused ultrasound; previous prostate surgery, including transurethral resection of the prostate; or missing data pertaining to essential variables.

3. Outcomes
-----------

The following key pathological features were evaluated from the radical prostatectomy pathology report: non-organ confined disease, any upgrading of the Gleason score, a specific increase in the Gleason score ≥ 7 (4+3), an unfavorable disease outcome, and insignificant cancer. The primary outcome for analysis was an unfavorable disease status, defined as non-organ confined disease or an upgrading of the Gleason score ≥ 7 (4+3). Insignificant cancer was defined as follows according to the Stamey criteria: organ-confined disease; a Gleason score ≤ 6; and a tumor volume \< 0.5 mL \[[@b11-crt-2016-477]\]. BCR-free survival, DSS and OS were also evaluated.

4. Statistics
-------------

Patients were randomly assigned to two groups, with about 75% of patients allocated to the 'training sample' used to identify the best selection criteria, and the remaining 25% assigned to the 'validation sample' used to externally validate the selection criteria. Random allocation was performed using SPSS ver. 21.0 (IBM Corp., Armonk, NY) as previously described \[[@b12-crt-2016-477]\]. Finally, 1,623 (76.3%) were included to the training sample and 503 (23.7%) in the validation sample.

Using the training sample, the association between preoperative clinicopathological factors from various AS criteria \[[@b3-crt-2016-477],[@b13-crt-2016-477]-[@b17-crt-2016-477]\] with primary and major secondary outcomes was evaluated. The following factors were evaluated: age; clinical stage (T1c, T2a); prostate size; PSA; PSA density, measured both as a continuous variable and categorical variable (\< 0.15, 0.15-0.2, and \> 0.2 ng/mL/mL); number of positive cores (1, 2, and ≥ 3); percent positive cores, defined as the number of positive cores/number of total cores; the maximum cancer involvement rate in any core, measured both as a continuous and categorical variable (≤ 20%, \> 20% and ≤ 50%, and \> 50%). Univariate logistic regression analyses were conducted to assess the association of each factor with an unfavorable disease outcome.

Subsequently, multivariate analysis with backward elimination using a probability for removal of 0.1 was performed. This analysis included all variables found to be significant by univariate analyses as a starting point. If both continuous and categorical forms of the same variable were significant upon univariate analysis, we selected a categorical form for better interpretation on multivariate analysis. The purpose of the multivariate analysis was to identify significant factors that would be used as selection criteria. For the analysis, we employed backward elimination, which can find the best fitted, reduced model. To rule out the effects of heterogeneity of the institutions, we conducted sensitivity analysis. We compared two multivariate logistic regression models, an original one and another model including institutions as the variables.

Univariate and multivariate Cox proportional regression analyses were performed to assess BCR-free survival using the same method. We also used a spline curve fitting method to visualize the odds ratio (OR) and hazard ratio (HR) according to significant continuous variables and to identify sensitive cut-off values for each retained significant factor. The results of these analyses were then used to develop new AS selection criteria for Korean patients with PC. Finally, we compared the validity of our selection criteria against various Western criteria \[[@b3-crt-2016-477],[@b13-crt-2016-477]-[@b17-crt-2016-477]\] in our study population in terms of key pathological features and BCR-free survival. We subsequently validated our criteria using the validation sample.

For statistical comparisons, a p-value of \< 0.05 was considered significant. Statistical analyses were performed using SPSS ver. 21.0, with curve fitting performed using R for Windows ver. 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results
=======

1. Patients' characteristics
----------------------------

Across the eight participating institutions, 2,433 patients met our inclusion criteria during the defined study period. After screening for exclusion criteria, the data of 2,126 patients were retained for the final analysis. Basic characteristics of our study cohort are summarized in [Table 1](#t1-crt-2016-477){ref-type="table"}. Overall, non-organ confined disease was identified in 14.9% (316/2,126) of cases, with a general upgrading of the Gleason score in 50.0% (1,063/2,126) of cases and an upgrading to a score ≥ 7 (4+3) in 8.7% (186/2,126) of cases. A final unfavorable disease status was defined in 20.8% (442/2,126) of cases. At the median follow-up period of 52 months, the 5- and 10-year BCR-free survival rate was 92.3% and 78.3%, respectively ([Fig. 1](#f1-crt-2016-477){ref-type="fig"}). The 10-year DSS and OS were 97.7% and 95.8%, respectively.

2. Factors associated with unfavorable disease outcome and BCR-free survival
----------------------------------------------------------------------------

The results of logistic regression analyses are reported in [Table 2](#t2-crt-2016-477){ref-type="table"}. With the exception of clinical stage, all variables evaluated by univariate logistic regression analysis were significantly associated with an unfavorable disease outcome. Among these, age, PSA density (as a categorical variable), number of positive biopsy cores and the maximum cancer involvement rate in any core (as a categorical variable) were retained as significant factors upon multivariate analysis. In the sensitivity analysis, the final multivariate logistic regression model was not significantly affected by the effects of the institutions ([S1 Table](#SD1-crt-2016-477){ref-type="supplementary-material"}).

Cox proportional regression analyzes are presented in [Table 3](#t3-crt-2016-477){ref-type="table"}. BCR-free survival was inversely associated with clinical stage, a PSA density \> 0.2 ng/mL/mL and the maximum cancer involvement rate in any core (as categorical variable) upon multivariable analysis. The curve fitting analysis is presented in [Fig. 2](#f2-crt-2016-477){ref-type="fig"}. A PSA density ≥ 0.15 ng/mL/mL was associated with a higher risk of unfavorable disease (OR \> 1) and a higher risk of BCR (HR \> 1). From this curve, we identified 1 or 2 positive biopsy cores and a maximum cancer involvement in any core ≤ 20% as cut-off criteria.

3. Suggestion of an appropriate AS selection criteria for Korean patients with PC, with comparison to Western AS criteria
-------------------------------------------------------------------------------------------------------------------------

Based on the aforementioned results, we identified the following criteria for appropriate AS in Korean patients with PC: a biopsy Gleason score ≤ 6; a clinical stage T1-T2a; a PSA ≤ 10 ng/mL and a PSA density \< 0.15 ng/mL/mL; a number of positive cores ≤ 2; and a maximum cancer involvement rate within any core ≤ 20%. Comparison of these criteria to established Western criteria is summarized in [Table 4](#t4-crt-2016-477){ref-type="table"}. Using our newly defined criteria, we could select more patients for AS (n=402) than when using the Johns Hopkins University criteria (n=381), which is considered to be the most stringent criteria for AS selection among training samples ([Table 5](#t5-crt-2016-477){ref-type="table"}). Our criteria also provided a lower unfavorable disease rate (11.7%) and higher insignificant cancer rate (12.0%) in our training sample than the Western criteria. The 10-year BCR-free survival was also the highest (91.7%) among all eligibility criteria. Furthermore, the unfavorable disease rate was only 5.9%, with a 10-year BCR-free survival of 96.7% in our validation sample, which confirmed our original results.

Discussion
==========

PC has been shown to be more aggressive in Asian populations than in Western populations due to ethnicity-specific factors and overall lower access to PSA screening \[[@b18-crt-2016-477]\]. Specifically for radical prostatectomy cases, even after adjusting for other factors, the Gleason score for Korean men is consistently higher and the disease status is more advanced than in African-American men, who are already at a significantly higher risk than Caucasian men for aggressive PC \[[@b19-crt-2016-477]\]. Moreover, the Gleason score has been reported to be higher for Asian-American patients than for Caucasian men, despite equal access to healthcare \[[@b20-crt-2016-477]\]. These epidemiological data clearly demonstrate the need for AS criteria specific to Asian populations. A study using the Johns Hopkins University criteria to evaluate a study group of patients who had undergone radical prostatectomy, revealed an upgrading of the Gleason score in 17.1% (322/1,892) of their cases, with an unfavorable disease outcome, defined as a non-organ confined disease or any upgrading of the Gleason score, in 22.3% (419/1,892) of their cases \[[@b21-crt-2016-477]\]. When applying this criteria and definition to our entire cohort, our rate of any upgrading of the Gleason score was 40.5% (210/518), with an unfavorable disease rate occurring in 43.1% (233/518) of cases. A recently published multicenter study in Japan reported a pathological outcome similar to ours \[[@b22-crt-2016-477]\], with a rate of upgrading of the Gleason score of 52.8% (150/284), and 14.1% (40/284) for upgrading to ≥ 7 (4+3). This study used the same definition of unfavorable disease outcome as our study, reporting an unfavorable disease rate of 21.1% (60/284). In the present study, we reported rates of up-grading of the Gleason score of 50.0%, upgrading to ≥ 7 (4+3) of 8.7%, and an unfavorable disease rate of 20.8% for our entire cohort, which were similar to previously reported trends in Asian populations. These results underline the caution that needs to be exerted when adopting a Western AS protocol for Asian populations.

A similar limitation of the usefulness of Western AS protocols for Asian patients with AS was demonstrated in the International Prostate Cancer Research: Active Surveillance (PRIAS) project, which aimed to prospectively evaluate AS with data from 18 countries, including Japan \[[@b23-crt-2016-477]\]. Notably, there was a high reclassification rate at the time of the first biopsy in the PRIAS-Japan protocol \[[@b24-crt-2016-477]\] of 33.8% compared to 24% for the global cohort \[[@b23-crt-2016-477],[@b24-crt-2016-477]\]. Based on these outcomes, the PRIAS-Japan research group agreed that a long-term follow-up is needed to determine if the PRIAS protocol could safely be used in Asian patients with PC. According to the data from Japan, a positive core rate was a strong predictor of reclassification \[[@b24-crt-2016-477]\]. Indeed, the reclassification rate was significantly lowered to 20.1% by using one positive core as a strict selection criterion. However, using these criteria, about 25% of patients who would benefit from AS would lose this opportunity.

From this perspective, we would like to emphasize that our new selection criteria for AS is not the *strictest* criteria, but we do consider it to be the most appropriate for Asian populations. Applying our criteria, we would select more patients for AS than would be selected using the Johns Hopkins University AS criteria (402 vs. 381, respectively), with these criteria being the most stringent \[[@b16-crt-2016-477]\]. Moreover, our selection criteria provided a lower rate of unfavorable disease outcome than was obtained using the John Hopkins criteria (11.7% vs. 13.4%, respectively), and a higher BCR-free survival rate (91.74% vs. 74.5%, respectively). Therefore, based on our criteria, we could offer AS to a greater proportion of patients with PC, without compromising the identification of patients who would benefit from definitive treatment.

Previous studies have evaluated AS selection criteria for Korean men, with some evidence of their usefulness \[[@b9-crt-2016-477],[@b25-crt-2016-477],[@b26-crt-2016-477]\]. However, these were single center studies that included a small number of patients or studies that only evaluated the applicability of Western AS criteria to Korean men. One Japanese prospective AS study attempted to develop their own AS protocol \[[@b27-crt-2016-477]\]. However, their selection of criteria was not based on concrete evidence, and were instead defined from existing criteria. In contrast, we defined our AS selection criteria based on research evidence and clinical rationale derived from a large scale, multicenter dataset.

Application of our findings is limited by the retrospective study design. Additionally, lack of central pathological review as well as the 2005 revision of the Gleason grading system, which likely influenced our results, are another limitation \[[@b28-crt-2016-477]\]. However, the pathologists in the participating centers were well experienced uropathologists; therefore, we believe that inter-rater variability would not be sufficient to alter our results. The heterogeneity of practice pattern for these patients across the eight included institutions could be another potential limitation. However, dedicated uro-oncologists managed these patients following standard practices in each institution; thus, this minor heterogeneity may enable generalization of the study in real practice scenario. We also confirmed minimal effects of institutions by sensitivity analysis. Recent studies have focused on the use of multi-parametric magnetic resonance imaging and the identification of new biomarkers to seek more appropriate AS selection criteria \[[@b29-crt-2016-477],[@b30-crt-2016-477]\]. As these emerging criteria have yet to be standardized, we could not incorporate this information into our analysis. Despite these limitations, our study offers several strengths, with the participation of centers with the highest volume of assessment and treatment of PC in Korea being a definite advantage that favors the general interpretation and clinical application of our criteria. Furthermore, as our new AS criteria uses only general clinicopathological factors, it is readily applicable to clinical practice.

In conclusion, Korean men with PC who are eligible for AS according to Western criteria are at a higher risk for upgrading of the Gleason disease score, unfavorable disease outcomes and long-term BCR than Western patients with PC. Our new selection criteria could help improve AS protocols in Korean men, and possibly other Asian populations. These criteria are: a clinical T1c-2a stage; a biopsy Gleason score ≤ 6; a pre-biopsy PSA ≤ 10 ng/mL and PSA density \< 0.15 ng/mL/mL; number of positive cores ≤ 2 among 10 or more total biopsy cores; and a maximum cancer involvement rate in any core ≤ 20%. With these new selection criteria, we identified more potential candidates for AS than when using the Johns Hopkins University AS criteria, while maintaining a lower rate of unfavorable disease and higher BCR-free survival then when using the John Hopkins criteria.

Prospective studies using these criteria are now warranted in Korea. However, further studies are still needed to determine the optimal follow-up protocol and better criteria for initiation of active treatment during surveillance. Additionally, the contribution of multi-parametric prostate magnetic resonance imaging to refining the criteria will need to be evaluated and considered.
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###### 

Basic characteristics of the patients (n=2,126)

  Characteristic                        Training sample (n=1,623)   Validation sample (n=503)
  ------------------------------------- --------------------------- ---------------------------
  **Age (yr)**                          64.7±6.9 (37-86)            65.0±7.2 (39-81)
  **Prostate size (mL)**                39.0±17.4 (7.8-141.0)       39.0±17.8 (12.0-162.0)
  **PSA (ng/mL)**                       5.4±2.0 (0.1-10.0)          5.3±1.9 (0.7-9.9)
  **PSA density (ng/mL/mL)**            0.16±0.09 (0-0.60)          0.15±0.08 (0.02-0.51)
  **Clinical T stage**                                              
   T1c                                  1,007 (62.0)                334 (66.4)
   T2a                                  616 (38.0)                  169 (33.6)
  **No. of positive biopsy cores**                                  
   1                                    750 (46.2)                  227 (45.1)
   2                                    350 (21.6)                  126 (25.0)
   \> 2                                 523 (32.2)                  150 (29.8)
  **Maximum involvement of core (%)**   25.5±21.0 (0.3-100)         25.1±20.5 (0.5-100)
  **Operation methods**                                             
   Open                                 767 (47.3)                  238 (47.3)
   Laparoscopic                         178 (11.0)                  65 (12.9)
   Robotic                              678 (41.8)                  200 (39.8)
  **Pathologic T stage**                                            
   T0                                   8 (0.5)                     4 (0.8)
   T2a-b                                371 (22.9)                  104 (20.7)
   T2c                                  1,008 (62.1)                315 (62.6)
   T3a                                  214 (13.2)                  74 (14.7)
   T3b                                  19 (1.2)                    6 (1.2)
   T4                                   3 (0.2)                     0
  **Lymph node involvement**            4 (0.2)                     1 (0.2)
  **Pathologic Gleason score**                                      
   ≤ 6                                  810 (49.9)                  253 (50.3)
   7 (3+4)                              666 (41.0)                  211 (41.9)
   7 (4+3)                              115 (7.1)                   31 (6.2)
   8                                    20 (1.2)                    4 (0.8)
   9                                    12 (0.7)                    4 (0.8)
  **Positive surgical margin**          281 (17.3)                  75 (14.9)
  **Follow-up duration (mo)**                                       
   Median                               53                          51
   Mean±SD                              55.2±28.0                   54.1±27.2

Values are presented as mean±SD (range) or number (%). PSA, prostate specific antigen; SD, standard deviation.

###### 

Logistic regression analyses for unfavorable disease

                                                            Univariate             Multivariate                      
  --------------------------------------------------------- ---------------------- -------------- ------------------ ----------
  **Age (yr)**                                              1.03 (1.01-1.04)       0.008          1.03 (1.01-1.05)   \< 0.001
  **cT stage, T2a vs. T1c**                                 1.26 (0.983-1.60)      0.068          \-                 \-
  **Prostate size (mL)**                                    0.98 (0.97-0.99)       \< 0.001       \-                 \-
  **PSA (ng/mL)**                                           1.09 (1.03-1.16)       0.006          \-                 \-
  **PSAD (cont.)**                                          46.83 (12.63-173.72)   \< 0.001       \-                 \-
  **PSAD (ng/mL/mL)**                                                              \< 0.001                          \< 0.001
   \< 0.15                                                  Reference                             Reference          
   0.15-0.2                                                 1.37 (0.99-1.89)       0.055          1.21 (0.86-1.72)   0.274
   \> 0.2                                                   2.09 (1.59-2.75)       \< 0.001       1.85 (1.37-2.51)   \< 0.001
  **Positive biopsy cores**                                                        \< 0.001                          0.008
   1                                                        Reference                             Reference          
   2                                                        1.33 (0.96-1.84)       0.091          1.24 (0.87-1.76)   0.232
   ≥ 3                                                      2.07 (1.58-2.73)       \< 0.001       1.62 (1.17-2.25)   0.004
  **Positive cores (%)**                                    1.02 (1.01-1.03)       \< 0.001       \-                 \-
  **Maximum cancer involvement rate in any core (cont.)**   1.02 (1.01-1.03)       \< 0.001       \-                 \-
  **Maximum cancer involvement rate in any core (%)**                              \< 0.001                          \< 0.001
   ≤ 20                                                     Reference                             Reference          
   \> 20 and ≤ 50                                           1.75 (1.32-2.31)       \< 0.001       1.42 (1.04-1.92)   0.025
   \> 50                                                    3.32 (2.31-4.77)       \< 0.001       2.35 (1.57-3.50)   \< 0.001

OR, odds ratio; CI, confidence interval; cT stage, clinical T stage; PSA, prostate specific antigen; PSAD, PSA density.

###### 

Cox proportional regression analyses for biochemical recurrence-free survival

                                                                    Univariate            Multivariate                      
  ----------------------------------------------------------------- --------------------- -------------- ------------------ -------
  **Age (yr)**                                                      1.00 (0.97-1.03)      0.968          \-                 \-
  **cT stage, T2a vs. T1c**                                         1.55 (1.08-2.23)      0.019          1.62 (1.09-2.40)   0.017
  **Prostate size (mL)**                                            1.00 (0.99-1.01)      0.729          \-                 \-
  **PSA (ng/mL)**                                                   1.15 (1.05-1.25)      0.003          \-                 \-
  **PSAD (cont.)**                                                  24.81 (3.96-155.49)   \< 0.001       \-                 \-
  **PSAD (ng/mL/mL)**                                                                     0.003                             0.067
   \< 0.15                                                          Reference                            Reference          
   0.15-0.2                                                         1.13 (0.68-1.88)      0.643          1.05 (0.61-1.81)   0.856
   \> 0.2                                                           1.96 (1.32-2.91)      \< 0.001       1.64 (1.06-2.53)   0.027
  **Positive biopsy cores**                                                               0.008                             \-
   1                                                                Reference                            \-                 
   2                                                                1.39 (0.86-2.24)      0.184          \-                 \-
   ≥ 3                                                              1.75 (1.16-2.65)      0.008          \-                 \-
  **Positive cores (%)**                                            1.01 (1.00-1.02)      0.037          \-                 \-
  **Maximum cancer involvement rate in any core (concentration)**   1.02 (1.01-1.02)      \< 0.001       \-                 \-
  **Maximum cancer involvement rate in any core (%)**                                     0.004                             0.039
   ≤ 20                                                             Reference                            Reference          
   \> 20 and ≤ 50                                                   1.78 (1.17-2.73)      0.008          1.64 (1.06-2.52)   0.025
   \> 50                                                            2.22 (1.29-3.83)      0.004          1.80 (1.02-3.16)   0.041

HR, hazard ratio; CI, confidence interval; cT stage, clinical T stage; PSA, prostate specific antigen; PSAD, PSA density.

###### 

Summary of our new criteria and various Western criteria for active surveillance

  Protocol            Biopsy Gleason score   cStage   PSA (ng/mL)   PSAD (ng/mL/mL)   No. of positive cores   Maximum cancer involvement rate in any core
  ------------------- ---------------------- -------- ------------- ----------------- ----------------------- ---------------------------------------------
  JHU (15)            ≤ 6                    T1c      \-            \< 0.15           ≤ 2                     ≤ 50
  PRIAS (13)          ≤ 6                    T1c-T2   ≤ 10          \< 0.2            ≤ 2                     \-
  Univ. Miami (14)    ≤ 6                    T1-T2    ≤ 15          \-                ≤ 2                     ≤ 20
  UCSF (12)           ≤ 6                    T1-T2    ≤ 10          \-                \< 33%                  ≤ 50
  MSKCC (16)          ≤ 6                    T1-T2a   ≤ 10          \-                ≤ 3                     ≤ 50
  Univ. Toronto (3)   ≤ 6                    T1-T2a   ≤ 10          \-                \-                      \-
  Present study       ≤ 6                    T1-T2a   ≤ 10          \< 0.15           ≤ 2                     ≤ 20

cStage, clinical stage; PSA, prostate specific antigen; PSAD, PSA density; JHU, Johns Hopkins University; PRIAS, Prostate Cancer Research International: Active Surveillance; Univ. Miami, University of Miami; UCSF, University of California at San Francisco; MSKCC, Memorial Sloan-Kettering Cancer Center; Univ. Toronto, University of Toronto.

###### 

Key pathological outcome and biochemical recurrence survival by various active surveillance eligibility criteria

  Protocol                               No (%)         5-Year BCRFS (%)   10-Year BCRFS (%)                                               
  -------------------------------------- -------------- ------------------ ------------------- ----------- ------------ ----------- ------ ------
  JHU (15)                               381 (23.5)     25 (6.6)           151 (39.6)          26 (6.8)    51 (13.4)    33 (8.7)    97.2   74.5
  PRIAS (13)                             858 (52.9)     82 (9.6)           363 (42.3)          69 (8.0)    136 (15.9)   74 (8.7)    94.2   83.0
  Univ. Miami (14)                       707 (43.6)     49 (6.9)           300 (42.4)          55 (7.8)    94 (13.3)    64 (9.2)    94.5   90.6
  UCSF (12)                              1,127 (69.4)   120 (10.6)         531 (47.1)          95 (8.4)    197 (17.5)   78 (7.0)    93.3   81.0
  MSKCC (16)                             1,113 (68.6)   119 (10.7)         523 (47.0)          95 (8.5)    196 (17.6)   78 (7.1)    93.7   79.6
  Univ. Toronto (3)                      1,623 (100)    228 (14.0)         813 (50.1)          147 (9.1)   336 (20.7)   95 (6.0)    91.9   79.9
  Our new criteria (training sample)     402 (24.8)     26 (6.5)           140 (34.8)          27 (6.7)    47 (11.7)    40 (10.1)   94.6   91.7
  Our new criteria (validation sample)   135 (26.8)     5 (3.7)            50 (37.0)           3 (2.2)     8 (5.9)      16 (12.0)   98.3   96.7

NOCD, non-organ confined disease; BCRFS, biochemical recurrence-free survival, Johns Hopkins University; JHU, Johns Hopkins University; PRIAS, Prostate Cancer Research International: Active Surveillance; Univ. Miami, University of Miami; UCSF, University of California at San Francisco; MSKCC, Memorial Sloan-Kettering Cancer Center; Univ. Toronto, University of Toronto.
